On December 20, the Central Epidemic Command Center (CECC) reported that based on the resolutions adopted on December 19 at the expert meeting of the Advisory Committee on Immunization Practices (ACIP) at the Ministry of Health and Welfare, ACIP recommendations on COVID-19 vaccination have been updated as follows after epidemic risks at home and abroad, vaccine supply in Taiwan, and vaccination policies in other countries were evaluated:
A. Members of the public who have received the first dose of a COVID-19 vaccine primary series can choose any COVID-19 vaccines approved by Taiwan's Food and Drug Administration as their second dose after being assessed to meet the required minimum interval by a physician.
B. People aged 12 or older who are assessed by a physician to be immunocompromised or have a weakened immune system should receive an additional dose at least 28 days after their second dose of a COVID-19 vaccine; such people are recommended to consider receiving an mRNA vaccine (e.g. Moderna, Pfizer-BioNTech) or a protein subunit vaccine (e.g. Medigen).
C. Individuals aged 18 or older who have completed their primary series vaccination for five months should get a booster dose and are recommended to consider receiving an mRNA vaccine (e.g. Moderna, Pfizer-BioNTech) or a protein subunit vaccine (e.g. Medigen) for adequate protection.
The above-mentioned policy will be implemented starting December 24. A letter with implementation details will be given to each local Department of Health, which will notify contracted COVID-19 vaccination healthcare facilities in the city or county, in the following days.